2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Serologic Tests, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

2189 No progressive deterioration of CT-derived vertebral bone attenuation during longitudinal follow-up of patients with monoclonal gammopathy of undetermined significance

Joselle M Cook, M.D., Nadine Abdallah I, MD2, Wilson Gonsalves, MD3, S. Vincent Rajkumar, MD4, Shaji Kumar, MD5, Mohammad Mustafa6, Rahma Warsame, MD7, Megan Weivoda, PhD8, Alex Weston, PhD9, Brandon Grossardt, MS10, Andrea Ferrero, PhD11, Stephen Broski, MD12, Sharmila Giri, MS13, Fang-Shu Ou, PhD14, Celine Vachon, PhD15, Francis Baffour, MD16
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States

Background: Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of skeletal complications, but whether CT-derived estimates of vertebral bone quality progressively deteriorates during the MGUS disease course before progression to multiple myeloma (MM) remains unknown. CT imaging also permits simultaneous assessment of skeletal muscle composition, another important determinant of musculoskeletal health. We evaluated longitudinal changes in CT-derived vertebral bone attenuation and body composition among patients with MGUS.

Methods: We performed a retrospective longitudinal study of patients with MGUS who underwent clinically acquired CT scans. Longitudinal trajectories of vertebral bone attenuation in Hounsfield’s units (HU) and CT-derived body composition measures at the L3 vertebral level were evaluated using multivariable linear mixed-effects models with patient-specific random intercepts and slopes, adjusted for age at MGUS diagnosis, sex, and timing of each scan relative to diagnosis. For patients who progressed to MM, imaging follow-up was censored at the time of MM diagnosis so that only pre-progression scans were analyzed.

Results: The cohort included 1,528 patients (mean age 67.8 years; 61.5% male) contributing 5,223 CT scans over median (IQR) follow up time of 4.26 (1.1, 7.17) years. Twenty-nine patients (1.9%) progressed to MM during follow-up. Mean bone attenuation was 310.86 (SD 121.66). The longitudinal trajectories differed between bone and skeletal muscle. Vertebral bone attenuation demonstrated a +3.3 HU/year increase over time (95% CI 1.7-4.9; P=0.0001), consistent with no clinically meaningful deterioration in vertebral bone quality during the MGUS disease course. In contrast, skeletal muscle composition showed declines in skeletal muscle area (-1.35 cm²/year, 95% CI -1.90 to -0.79; P<0.0001) and muscle attenuation (-0.47 HU/year, 95% CI -0.70 to -0.24; P=0.0001), accompanied by increasing intermuscular adipose tissue (+0.38 cm²/year, 95% CI 0.23-0.52; P<0.0001). Visceral adipose tissue remained stable (P=0.843), whereas subcutaneous adipose tissue declined over time (-2.24 cm²/year, P=0.006). Older age at MGUS diagnosis was independently associated with lower vertebral bone attenuation. The limited number of MM progression events precluded meaningful comparisons of imaging trajectories between progressors and non-progressors.

Conclusions: Despite the known skeletal fragility associated with MGUS, these CT-derived vertebral bone attenuation measures remained stable over time in this large longitudinal cohort, providing no evidence of progressive vertebral bone deterioration. This study provides one of the first comprehensive longitudinal characterizations of CT-derived musculoskeletal measures during the MGUS disease course.

Joselle M Cook, M.D.: Kite Pharmaceuticals - Honoraria; Janssen Pharmaceuticals - Research Funding; Regeneron - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)